95 related articles for article (PubMed ID: 9191956)
1. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework.
Giardina GA; Sarau HM; Farina C; Medhurst AD; Grugni M; Raveglia LF; Schmidt DB; Rigolio R; Luttmann M; Vecchietti V; Hay DW
J Med Chem; 1997 Jun; 40(12):1794-807. PubMed ID: 9191956
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.
Hay DW; Giardina GA; Griswold DE; Underwood DC; Kotzer CJ; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Martin LD; Kilian D; Legos JJ; Barone FC; Luttmann MA; Grugni M; Raveglia LF; Sarau HM
J Pharmacol Exp Ther; 2002 Jan; 300(1):314-23. PubMed ID: 11752131
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists.
Medhurst AD; Hay DW; Parsons AA; Martin LD; Griswold DE
Br J Pharmacol; 1997 Oct; 122(3):469-76. PubMed ID: 9351503
[TBL] [Abstract][Full Text] [Related]
6. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.
Blaney FE; Raveglia LF; Artico M; Cavagnera S; Dartois C; Farina C; Grugni M; Gagliardi S; Luttmann MA; Martinelli M; Nadler GM; Parini C; Petrillo P; Sarau HM; Scheideler MA; Hay DW; Giardina GA
J Med Chem; 2001 May; 44(11):1675-89. PubMed ID: 11356103
[TBL] [Abstract][Full Text] [Related]
7. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Sarau HM; Griswold DE; Potts W; Foley JJ; Schmidt DB; Webb EF; Martin LD; Brawner ME; Elshourbagy NA; Medhurst AD; Giardina GA; Hay DW
J Pharmacol Exp Ther; 1997 Jun; 281(3):1303-11. PubMed ID: 9190866
[TBL] [Abstract][Full Text] [Related]
8. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
9. 2-Phenyl-4-quinolinecarboxamides: a novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor.
Giardina GA; Sarau HM; Farina C; Medhurst AD; Grugni M; Foley JJ; Raveglia LF; Schmidt DB; Rigolio R; Vassallo M; Vecchietti V; Hay DW
J Med Chem; 1996 Jun; 39(12):2281-4. PubMed ID: 8691422
[No Abstract] [Full Text] [Related]
10. Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model.
Choppin A; Groke G; Bringas A; Stepan G; Dillon MP
Pharmacology; 2002 May; 65(2):96-102. PubMed ID: 11937780
[TBL] [Abstract][Full Text] [Related]
11. Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists.
Giardina GA; Artico M; Cavagnera S; Cerri A; Consolandi E; Gagliardi S; Graziani D; Grugni M; Hay DW; Luttmann MA; Mena R; Raveglia LF; Rigolio R; Sarau HM; Schmidt DB; Zanoni G; Farina C
Farmaco; 1999 Jun; 54(6):364-74. PubMed ID: 10443017
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of 2-(4-biphenylyl)quinoline-4-carboxylate and carboxamide analogs. New human neurokinin-3 (hNK-3) receptor antagonists.
Saudi MN; Rostom SA; Fahmy HT; El Ashmawy IM
Arch Pharm (Weinheim); 2003 Jun; 336(3):165-74. PubMed ID: 12822182
[TBL] [Abstract][Full Text] [Related]
13. Functional expression of a novel human neurokinin-3 receptor homolog that binds [3H]senktide and [125I-MePhe7]neurokinin B, and is responsive to tachykinin peptide agonists.
Krause JE; Staveteig PT; Mentzer JN; Schmidt SK; Tucker JB; Brodbeck RM; Bu JY; Karpitskiy VV
Proc Natl Acad Sci U S A; 1997 Jan; 94(1):310-5. PubMed ID: 8990205
[TBL] [Abstract][Full Text] [Related]
14. Activation of the cloned human NK3 receptor in Chinese Hamster Ovary cells characterized by the cellular acidification response using the Cytosensor microphysiometer.
Jordan RE; Smart D; Grimson P; Suman-Chauhan N; McKnight AT
Br J Pharmacol; 1998 Oct; 125(4):761-6. PubMed ID: 9831912
[TBL] [Abstract][Full Text] [Related]
15. Bronchoconstrictor effect of the tachykinin NK₃-receptor agonists [MePhe⁷]-neurokinin B and senktide in the isolated guinea pig lung.
Corboz MR; Rivelli MA; Eckel SP
Exp Lung Res; 2010 Nov; 36(9):509-21. PubMed ID: 20939761
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of mucin secretion from CHO-K1-hNK(1)R cells.
Caccese R; Graham A; Bialecki R
Neuropeptides; 1999 Jun; 33(3):239-43. PubMed ID: 10657498
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of cloned human NK-2 (neurokinin A) receptor expressed in a baculovirus/Sf-21 insect cell system.
Aharony D; Little J; Powell S; Hopkins B; Bundell KR; McPheat WL; Gordon RD; Hassall G; Hockney R; Griffin R
Mol Pharmacol; 1993 Aug; 44(2):356-63. PubMed ID: 8394992
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
19. Evidence that the proposed novel human "neurokinin-4" receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human origin.
Sarau HM; Mooney JL; Schmidt DB; Foley JJ; Buckley PT; Giardina GA; Wang DY; Lee JA; Hay DW
Mol Pharmacol; 2000 Sep; 58(3):552-9. PubMed ID: 10953048
[TBL] [Abstract][Full Text] [Related]
20. GR138676, a novel peptidic tachykinin antagonist which is potent at NK3 receptors.
Stables JM; Beresford IJ; Arkinstall S; Ireland SJ; Walsh DM; Seale PW; Ward P; Hagan RM
Neuropeptides; 1994 Dec; 27(6):333-41. PubMed ID: 7534879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]